Immunovant Inc(IMVT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:00 PM ET (Korea 10/27 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.81 | Insider Own | 58.93% | Shs Outstand | 206.3M | Perf Week | 1.99% |
| Market Cap | 5.82B | Forward P/E | - | EPS next Y | 0.58% | Insider Trans | -0.3% | Shs Float | 84.8M | Perf Month | -15.41% |
| Enterprise Value | 5.02B | PEG | - | EPS next Q | -0.74 | Inst Own | 52.25% | Short Float | 20.53% | Perf Quarter | -27.58% |
| Income | -0.54B | P/S | - | EPS this Y | -6% | Inst Trans | 0.53% | Short Ratio | 13.12 | Perf Half Y | -1.57% |
| Sales | 0.00B | P/B | 7.9 | EPS next 5Y | 12.21% | ROA | -71.1% | Short Interest | 17.42M | Perf YTD | 10.82% |
| Book/sh | 3.57 | P/C | 7.29 | EPS past 3/5Y | -17.37% -17.75% | ROE | -80.1% | 52W High | -37.98% ($45.42) | Perf Year | 48.73% |
| Cash/sh | 3.86 | P/FCF | - | Sales past 3/5Y | - | ROIC | -73.19% | 52W Low | 50.32% ($18.74) | Perf 3Y | -17.75% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 1.28% | Gross Margin | - | Volatility(W/M) | 4.27% 4% | Perf 5Y | 253.01% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.26 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.27 | EPS Q/Q | -5.6% | Profit Margin | - | RSI (14) | 31.02 | Recom | 1.47 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.27 | Sales Q/Q | - | SMA20 | -6.6% ($30.16) | Beta | 0.94 | Target Price | $48.88 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/11/9 | SMA50 | -21.23% ($35.76) | Rel Volume | 0.9 | Prev Close | $28.41 |
| Employees | 315 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -19.26% - | SMA200 | -11.92% ($31.98) | Avg Volume(3M) | 1.33M | Price | $28.17 |
| IPO | 2019/6/21 | Option/Short | Yes/Yes | Trades | 9669 | Volume | 1,195,312 | Change | -0.84% |
🧬 This is a clinical-stage biotech company developing antibody therapeutics for autoimmune diseases. Leveraging immune antibody modulation mechanisms, it is developing next-generation antibody candidates targeting multiple autoimmune conditions such as myasthenia gravis and thyroid eye disease. As a biotech healthcare stock, its share price is driven by clinical results and funding conditions.
Over the past 1 year, roughly in the middle
38% below its 1-year high.
Traded about as much as usual. That is 90% of its average volume.
Next earnings report: November 9
13 days to go.
IMVT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -6.0% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +253.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
20.5% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #43 of 594 in the industry
Based on market cap of $6B.
FAQ
What kind of company is IMVT?
IMVT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IMVT?
The market cap of IMVT is approximately $5.8B, ranking 1,231 within its sector.
What is the 52-week high and low for IMVT?
IMVT has recorded a 52-week high of $45.42 and a low of $18.74.
